Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A "Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria" BMC Infectious Diseases 5: Art. No. 24 APR 8 2005

[Eugene Garfield]

E-mail Addresses:
Correspondence to : matthew.falagas at tufts.edu

Other Authors     :
j.bliziotis at alfahc.gr
s.kasiakou at alfahc.gr
georgsec at med.uoc.gr
alfa.healthcare at alfahc.gr
amichalopoulos at hol.gr


Title: Outcome of infections due to pandrug-resistant (PDR)
       Gram-negative bacteria

Author(s): Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G,
       Athanassopoulou P, Michalopoulos A

Source: BMC INFECTIOUS DISEASES 5: Art. No. 24 APR 8 2005

Document Type: Article    Language: English
Cited References: 27      Times Cited: 0

Abstract:
Background: The increasing problem of infections due to multidrug-resistant
Gram-negative bacteria has led to re-use of polymyxins in several
countries. However, there are already clinical isolates of Gram-negative
bacteria that are resistant to all available antibiotics, including
polymyxins.

Methods: We present a case series of patients with infections due to
pathogens resistant to all antimicrobial agents tested, including
polymyxins. An isolate was defined as pandrug-resistant (PDR) if it
exhibited resistance to all 7 anti-pseudomonal antimicrobial agents, i.e.
antipseudomonal penicillins, cephalosporins, carbapenems, monobactams,
quinolones, aminoglycosides, and polymyxins.

Results: Clinical cure of the infection due to pandrug-resistant ( PDR)
Gram-negative bacteria, namely Pseudomonas aeruginosa or Klebsiella
pneumoniae was observed in 4 out of 6 patients with combination of colistin
and beta lactam antibiotics.

Conclusion: Colistin, in combination with beta lactam antibiotics, may be a
useful agent for the management of pandrug-resistant Gram-negative
bacterial infections. The re-use of polymyxins, an old class of
antibiotics, should be done with caution in an attempt to delay the rate of
development of pandrug-resistant Gram-negative bacterial infections.

KeyWords Plus: PSEUDOMONAS-AERUGINOSA; CYSTIC-FIBROSIS; POLYMYXIN
RESISTANCE; ANTIBIOTIC-RESISTANCE; OUTER-MEMBRANE; COLISTIN; INVOLVEMENT;
RIFAMPIN; TAIWAN; UK

Addresses: Falagas ME (reprint author), Alfa Inst Biomed Sci, Athens, Greece
Alfa Inst Biomed Sci, Athens, Greece
Tufts Univ, Sch Med, Boston, MA 02111 USA
Alfa Healthcare, Athens, Greece
Univ Crete, Sch Med, Univ Hosp, Dept Med, Iraklion, Greece
Henry Dunant Hosp, Intens Care Unit, Athens, Greece

E-mail Addresses: matthew.falagas at tufts.edu, j.bliziotis at alfahc.gr,
s.kasiakou at alfahc.gr, georgsec at med.uoc.gr, alfa.healthcare at alfahc.gr,
amichalopoulos at hol.gr

Publisher: BIOMED CENTRAL LTD, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON
W1T 4LB, ENGLAND

IDS Number: 922FL

ISSN: 1471-2334

Cited References:
*NAT COMM CLIN LAB, 1981, M2A2S2 NCCLS.
BENGOECHEA JA, 2000, MOL MICROBIOL, V37, P67.
CATCHPOLE CR, 1997, J ANTIMICROB CHEMOTH, V39, P255.
CIOFU O, 2001, J ANTIMICROB CHEMOTH, V48, P391.
DENTON M, 2002, PEDIATR PULM, V34, P257.
FALAGAS ME, 2005, IN PRESS CLIN INFECT.
GALES AC, 2001, J CLIN MICROBIOL, V39, P183.
GARNACHOMONTERO J, 2003, CLIN INFECT DIS, V36, P1111.
GAYNES RP, 1996, HOSP EPIDEMIOLOGY IN, P1.
GIAMARELLOSBOURBOULIS EJ, 2002, DIAGN MICR INFEC DIS, V44, P259.
GIAMARELLOSBOURBOULIS EJ, 2003, J CHEMOTHERAPY, V15, P235.
GROISMAN EA, 1997, J BACTERIOL, V179, P7040.
GUNDERSON BW, 2003, ANTIMICROB AGENTS CH, V47, P905.
GUNN JS, 1998, MOL MICROBIOL, V27, P1171.
HSUEH PR, 2002, EMERG INFECT DIS, V8, P827.
ITOKAGAWA M, 1980, J ANTIBIOT TOKYO, V33, P1551.
KUO LC, 2003, J FORMOS MED ASSOC, V102, P601.
MANIKAL VM, 2000, CLIN INFECT DIS, V31, P101.
MICHALOPOULOS AS, 2005, CLIN MICROBIOL INFEC, V11, P115.
MOORE RA, 1984, ANTIMICROB AGENTS CH, V26, P539.
MOORE RA, 1986, ANTIMICROB AGENTS CH, V30, P923.
NICAS TI, 1980, J BACTERIOL, V143, P872.
PITT TL, 2003, THORAX, V58, P794.
RYNN C, 1999, CLIN MICROBIOL INFEC, V5, P32.
SPENCE RP, 2002, J MED MICROBIOL, V51, P1107.
TAMM M, 2000, SCHWEIZ MED WSCHR, V130, P1366.
VALERO E, 2001, REV ESP QUIMIOTERAP, V14, P358.